Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | TTK | P33981 | 3/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | GRK2 | P25098 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378060 | 0.90 | AURKA (0.61) | AURKAITKMAPK1TTKMAPK8 | |
| SCHEMBL5386918 | 0.88 | TTK (0.56) | AURKAITKMAPK1TTKMAPK8 | |
| SCHEMBL5379531 | 0.87 | TTK (0.60) | AURKATTKMAPK8ROCK2ROCK1 | |
| SCHEMBL6844212 | 0.85 | TTK (0.53) | AURKATTKMAPK8MAP2K7 | |
| SCHEMBL8260275 | 0.85 | TTK (0.61) | AURKAMAPK1TTKMAPK8 | |
| SCHEMBL5381231 | 0.85 | AURKA (0.59) | AURKANAMPTITKMAPK1TTK | |
| SCHEMBL5387166 | 0.85 | AURKA (0.63) | AURKAITKTTKMAPK8MAP2K7 | |
| SCHEMBL8260259 | 0.84 | TTK (0.52) | AURKATTKMAPK8MAP2K7 | |
| SCHEMBL5378112 | 0.83 | AURKA (0.52) | AURKAMAPK1TTKMAPK8MAP2K7 | |
| SCHEMBL5800969 | 0.83 | TTK (0.59) | AURKANAMPTITKMAPK1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | AURKA 3307/4885NAMPT 2663/4885ITK 1780/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | AURKA 2787/4885NAMPT 551/4885ITK 1770/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | AURKA 1439/4885NAMPT 514/4885ITK 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.